Legal
Filter News
Found 9,942 articles
-
Following the regulator’s administrative complaint and threat of a lawsuit in federal court, Sanofi has decided to terminate its licensing deal with Maze Therapeutics to avoid a long litigation process.
-
MustGrow Biologics and Bayer Sign Commercial License Agreement for Biocontrol Technologies in Europe, Middle East and Africa
12/11/2023
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) ("MustGrow") is pleased to announce the signing of a collaboration agreement (the "Agreement") with Bayer AG (FSE: BAYN) ("Bayer") covering soil applications of MustGrow's mustard-based biocontrol technologies in Europe, Middle East and Africa, excluding home and garden, turf and ornamental applications.
-
Plexxikon, which was acquired by Daiichi Sankyo, and Novartis have agreed to settle a patent case involving the cancer drug Tafinlar and its sale in the U.S.
-
Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.
-
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
12/4/2023
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023.
-
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
12/1/2023
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.
-
The two companies have settled all pending U.S. patent litigation, clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of Stelara.
-
The troubled Indian pharma company received its second FDA warning letter in months, which this time cited quality control and data integrity lapses at its manufacturing facility in Gujarat, India.
-
Pfizer and BioNTech scored a win over Moderna on Tuesday as the European Patent Office decided that a key patent held by the Massachusetts biotech related to its COVID-19 vaccine is invalid.
-
White House and Congress Propose AI Legislation as FDA Continues to Act as AI Regulatory Gatekeeper
11/22/2023
Both the White House and Congress have proposed legislation for the appropriate use of AI while the FDA continues to serve as the gatekeeper for patient privacy and safety. -
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
11/17/2023
Exact Sciences Corp. today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware.
-
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
11/13/2023
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the "Notice") from Cboe Canada ("Cboe") indicating that Awakn is not in compliance with Section 3.01(3) of Cboe's Listing Manual. Awakn has 90 days to address the non-compliance.
-
The Federal Trade Commission is challenging over 100 pharmaceutical patents held by prominent drugmakers, including AbbVie, AstraZeneca and Boehringer Ingelheim, for their listings.
-
The U.S. government has requested that a Delaware federal judge deny an AstraZeneca motion for summary judgement in its Inflation Reduction Act case, arguing that the company’s core claims are meritless.
-
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
11/3/2023
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group
-
Here’s how expanding companies can benefit from executive-level strategic experience in key areas while staying lean and nimble.
-
The moment of coming out of stealth mode is ripe for biotechs to stumble. Here’s how to get it right.
-
MediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to Cash
10/25/2023
MediPharm Labs Corp. is pleased to announce it has now received $7.27 Million in gross cash proceeds from the settlement agreement announced on October 2, 2023 to resolve a claim in connection with a commercial agreement dispute.
-
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
10/20/2023
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its intention to file a petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
-
Mindset Pharma Announces Shareholder Approval of Arrangement
10/20/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023